
Opinion|Videos|January 27, 2025
Biomarkers in Alzheimer’s Disease
Advertisement
Episodes in this series

Advertisement
Related to this article

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.

The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.

A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
2
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
3
Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease
4
Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial
5


